Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

(2021) Florentino Carral San Laureano et al.   JOURNAL OF INVESTIGATIVE MEDICINE

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design

(2020) Tadej Battelino et al.   Diabetes Therapy

Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study

(2020) Hiroshi Miura et al.   DIABETES OBESITY & METABOLISM

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study

(2020) Luigi Laviola et al.   Diabetes Therapy

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study

(2019) Jeremy Pettus et al.   Diabetes Therapy

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

(2019) Nikolaos Tentolouris et al.   ADVANCES IN THERAPY

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

(2019) Tadej Battelino et al.   DIABETES CARE

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)

(2019) Timothy S. Bailey et al.   DIABETES OBESITY & METABOLISM

Switching to Degludec from Other Basal Insulins is Associated with Reduced Hypoglycemia Rates: a Prospective Study

(2019) Gian Paolo Fadini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

(2018) T.S. Bailey et al.   DIABETES & METABOLISM

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin

(2018) Fang Liz Zhou et al.   DIABETES OBESITY & METABOLISM

Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial

(2018) Lutz Heinemann et al.   LANCET

Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Degludec in Patients with Type 2 Diabetes: A Randomized, Open-Label, Crossover Study Using Continuous Glucose Monitoring Profiles

(2018) Yuji Kawaguchi et al.   Journal of Diabetes Investigation

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

(2018) Julio Rosenstock et al.   DIABETES CARE

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

(2018) Lawrence Blonde et al.   ADVANCES IN THERAPY

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

(2018) Francesca Porcellati et al.   DIABETES CARE

Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections

(2017) Roy W. Beck et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

(2016) Tim Heise et al.   DIABETES OBESITY & METABOLISM

Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial

(2016) Jan Bolinder et al.   LANCET

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

(2016) Cornelis A J van Beers et al.   Lancet Diabetes & Endocrinology

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

(2015) Philip D. Home et al.   DIABETES CARE

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

(2015) Kellee M. Miller et al.   DIABETES CARE

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

(2015) M. C. Riddle et al.   DIABETES OBESITY & METABOLISM

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial

(2012) T. Battelino et al.   DIABETOLOGIA

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups

(2011) Nathan R. Hill et al.   Diabetes Technology & Therapeutics